![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.628, 2011-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
NZ Pharmac saves, but says no to imatinib mesylate
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 374, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmac announces new funding decisions
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 618, 2010-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmac funds type 2 DM drug, sets 3-year funding path
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 461, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmac doing a good job in New Zealand?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 248, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
NZ imposes new subsidy restrictions for anticonvulsants
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 283, 2000-01 ,pp. :